Pharmacokinetic analysis of venetoclax and treatment outcome in patients with acute myelogenous leukemia

Pharmacokinetic analysis of venetoclax and treatment outcome in patients with acute myelogenous leukemia - Pharmacokinetic analysis of venetoclax and treatment outcome in patients with acute myelogenous leukemia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047371

Enrollment

100

Registered

2022-04-02

Start date

2021-11-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myelogenous leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed as having AML and treated with regimes including venetoclax at least for 1 week. 2) 20 years old or older. 3) Agree with ICF.

Exclusion criteria

Exclusion criteria: 1) Disagree with ICF. 2) Patients who lack medical adherence. 3) Patients who are otherwise considered ineligible for the study by the investigator.

Design outcomes

Primary

Measure	Time frame
To examine the relevance between the blood concentration of venetoclax and treatment response, such as CR rate and duration of response	—

Secondary

Measure	Time frame
To examine the relevance between the blood concentration of venetoclax and adverse events (hematological AEs, tumor-lysis syndrome, infections)	—

Countries

Japan

Contacts

Public ContactTakeshi Kondo

Aiiku Hospital Blood Disorders Center

kondo@aiiku-hp.or.jp+81-11-563-2211

Outcome results